Alfacell to Present at Second International Symposium on Malignant Mesothelioma
The presentation, entitled, "Two ONCONASE® Clinical Trials in MM Patients Evaluated Using the EORTC Prognostic Model," will analyze whether there is a difference in survival between ONCONASE study patients categorized as 'Good' or 'Poor' risk for survival, using European Organization for the Research and Treatment of Cancer (EORTC) prognostic scores.
BLOOMFIELD, NJ – Oct. 4 – Alfacell Corporation (Nasdaq: ACEL - News) today announced that the Company will present at the Second International Symposium on Malignant Mesothelioma, to be held in Las Vegas from October 6– 8, 2005.
The presentation, entitled, "Two ONCONASE® Clinical Trials in MM Patients Evaluated Using the EORTC Prognostic Model," will analyze whether there is a difference in survival between ONCONASE study patients categorized as 'Good' or 'Poor' risk for survival, using European Organization for the Research and Treatment of Cancer (EORTC) prognostic scores. The EORTC model was recently validated in a study from St. Bartholomew's Hospital (Lung Cancer and Mesothelioma Unit, Medical Oncology) and The London Lung Cancer Group – both based in London, UK – published in the Journal of Clinical Oncology (Volume 23:1, January 1, 2005).
Alfacell, along with companies such as Eli Lilly, Merck and Fujirebio Diagnostics, has provided an educational grant in support of the symposium, which is organized by the Mesothelioma Applied Research Foundation (MARF), a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease. For more information on the symposium or MARF, visit www.marf.org.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
